Open AccessEvaluation of EOS Gene Expression and IL-6 Serum Levels in Iraqi Patients with Psoriasis
Author(s) -
Shawq Al-Naqqash,
Mohammed Mahdi Jawad,
Zainab Thamer Showait Al-Asady,
Sarmed Adnan Abdulrazaq
Publication year - 2021
Publication title -
al-rafidain journal of medical sciences.
Language(s) - English
Resource type - Journals
ISSN - 2789-3219
DOI - 10.54133/ajms.v1i.36
Subject(s) - etanercept , psoriasis , medicine , immune system , immunology , inflammation , interleukin 17 , psoriasis area and severity index , gene expression , gene , tumor necrosis factor alpha , biology , biochemistry
Background: EOS (encoded by the IKZF4 gene) is a member of the zinc finger transcription factor IKaros family, and plays a critical role in Treg suppressor functions, and maintaining Treg stability. IL-6 is a soluble mediator with a pleiotropic effect on inflammation, immune response, and hematopoiesis. Aim: To estimate serum IL-6 level and EOS gene expression in Iraqi patients with psoriasis. Method: Twenty-two patients with psoriasis (8 females, 14 males) with age ranged 18-72 years, were recruited from Baghdad Teaching Hospital, Dermatology Clinic, Baghdad, and 24 healthy donors. The serum levels of IL-6 by ELISA and the gene expression of IKZF4 (EOS gene) by RT-qPCR technique. Results: The results showed a non-significant difference in the level of IL-6 in those treated with topical therapy and others treated with Etanercept compared to control. A non-significant increase in patients treated with topical therapy was reported compared to patients treated with Etanercept. There was a higher significant percentage of IKZF4 gene expression folding in psoriasis patients treated with Etanercept compared to control group, while no significant differences reported between patients treated with topical therapy, Etanercept, and the control group. Conclusion: Activation of Regulatory T cells (Tregs) with Etanercept enhances EOS expression and decreases IL-6 production more than topical treatment in patients with psoriasis.